Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients
R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail
  • Phase

    Phase 3
  • Study Type

  • Status

    Unknown status
  • Study Participants

Primary objective:

To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell to R-CHOP therapy with DLBCL patients.
Study Started
Sep 30
Primary Completion
Sep 30
Study Completion
Sep 30
Last Update
Jun 28

Biological NKM injection

NKCell about 100mg IV for 6times in each chemotherapy period.

  • Other names: NKCell

control No Intervention

Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.

Active Active Comparator

R-CHOP plus Natural Killer Cell therapy


Inclusion Criteria:

Men and women of the age between 20 and 70
The patients who have measurable lesion using radiograph and have not received chemotherapy and radiation therapy after confirming DCBCL.
The patients with Ann arbor Ⅰ, Ⅱ, Ⅲ, Ⅳ
The patients who have not received NK / T-Cell lymphocyte therapy.
The patients who are expected to survive for at least 3 months.
The patients who or whose representative voluntary have written informed consent before performance of any study-related procedure.
Women of child bearing potential must have a negative pregnancy test within 7 days prior to study registration and agree to use adequate birth control during study treatment.
The patients with ADL classification (ECOG) scale 0, 1, 2

Patients who satisfy following hematologic criteria

WBC ≥ 3,000 / ㎕
platelet count ≥ 75,000 / ㎕
serum total bilirubin ≤ two times of upper limit of normal values of each laboratory
serum creatinine ≤ two times of upper limit of normal values of each laboratory

lymphoma patients who satisfy the following criteria

good renal function (GFR> 50)
good hepatic function (total bilirubin level ≤ three times of upper limit of normal values of each test laboratory transaminases ≤ 5 times of the upper limit of normal value of each testing laboratory)
The patients with negative HIV surface antigen
The patients with negative HBV
The patients with negative HCV
The patients who have not received immunotherapy.
The patients who have not experienced tuberculosis infection within recent 6 months.

Exclusion Criteria:

The minors under 20 years of age (In accordance with Civil Code)
The patients diagnosed with other types of lymphoma
The patients who have central nervous system or meningeal involvement by lymphoma.
The patients who have contraindication of chemotherapy regimen
The patients with another active severe disease.
The patients who have history of cancer within 5 years
Uncontrolled hypertension patients
The patients who have hypersensitivity to Erythropoietin.

The patients who have the following diseases or the experience to have following disease within 3 months.

Myocardial infarction
Unstable coronary disease
Uncontrolled cardiac insufficiency.
Venous thrombosis
Pulmonary embolism
The patients who have experience to be treated with the pharmaceutical for clinical trials.
Pregnant and lactating women or women of childbearing age not using adequate contraceptive method.
The patients with clinically serious bacterial, viral or fungal infection
The patients of the test group who have the problem in NK cell cultures (Investigator will decide on this criteria with basis generated during NK cell culture)
Patients with autoimmune diseases
The patients who underwent visceral resection related with Lymphoma.
No Results Posted